Lexicon Pharmaceuticals (NASDAQ:LXRX) Issues Quarterly Earnings Results

Key Points

• Lexicon beat Q3 expectations, reporting a loss of $0.03 per share versus the $0.06 loss analysts forecast, and revenue of $11.25 million versus estimates of $4.14 million.
• The Phase 3 SONATA-HCM trial completed enrollment with 542 patients; top-line results are expected in Q1 2027. Lexicon also pushed its planned ZYNQUISTA NDA resubmission to Q1 2027.
• Despite the earnings beat, Lexicon remained loss-making: its quarterly net loss widened to $14.0 million from $12.8 million a year earlier. It ended the quarter with $183.2 million in cash, equivalents and short-term investments.

Lexicon Pharmaceuticals (NASDAQ:LXRX - Get Free Report) released its quarterly earnings results on Thursday. The biopharmaceutical company reported ($0.03) EPS for the quarter, topping the consensus estimate of ($0.06) by $0.03, FiscalAI reports. The company had revenue of $11.25 million for the quarter, compared to analyst estimates of $4.14 million. Lexicon Pharmaceuticals had a negative return on equity of 35.88% and a negative net margin of 161.80%.

Here are the key takeaways from Lexicon Pharmaceuticals' conference call:

• SONATA-HCM enrollment is complete, with 542 patients enrolled, including 440 with non-obstructive HCM. Top-line results are expected in Q1 2027; efficacy remains unproven pending the readout.
• Lexicon now expects to resubmit the ZYNQUISTA NDA in type 1 diabetes in Q1 2027, later than initially anticipated, as it prepares the investigator-led STENO1 dataset to regulatory standards. The company said STENO1’s DKA rate was about one event per 100 patient-years and comparable to standard of care, but FDA review and approval remain uncertain.
• Early preclinical studies showed pilavapadin reduced body weight by 14% alone and 31% combined with semaglutide, versus 25% with semaglutide alone. The obesity opportunity is preliminary, and the company said further studies are needed.
• Third-quarter revenue fell to $11.3 million from $14.2 million a year earlier, while net loss widened to $14.0 million from $12.8 million. Cash, cash equivalents and short-term investments were $183.2 million at quarter-end, and 2026 operating expense guidance was maintained at $100 million to $110 million.
• Novo Nordisk’s LX9851 phase I program is progressing, and Lexicon received its third $10 million milestone payment from Novo this year. Additional milestone payments may be possible as development advances.

Lexicon Pharmaceuticals Stock Up 10.6%

Lexicon Pharmaceuticals stock traded up $0.17 during mid-day trading on Friday, reaching $1.78. 3,598,478 shares of the company were exchanged, compared to its average volume of 1,937,201. The firm's 50-day simple moving average is $1.81 and its two-hundred day simple moving average is $1.89. Lexicon Pharmaceuticals has a twelve month low of $1.10 and a twelve month high of $2.68. The company has a quick ratio of 13.29, a current ratio of 13.37 and a debt-to-equity ratio of 0.29.

Lexicon Pharmaceuticals News Roundup

Here are the key news stories impacting Lexicon Pharmaceuticals this week:

• Positive Sentiment: Lexicon posted a Q3 loss of $0.03 per share, narrower than the $0.06 loss analysts expected and the $0.04 loss a year earlier. Revenue of $11.25 million also topped estimates of about $4.14 million. Zacks earnings report
• Positive Sentiment: The Phase 3 SONATA-HCM trial is substantially overenrolled, with top-line results expected in Q1 2027. This could provide a significant upcoming clinical catalyst. Lexicon clinical and financial update
• Positive Sentiment: Lexicon said positive STENO1 safety data strengthen the benefit-risk profile for a ZYNQUISTA NDA resubmission, potentially advancing another path to value creation. Lexicon clinical and financial update
• Neutral Sentiment: Phase 1 clinical development of LX9851 is ongoing at Novo Nordisk; the update indicates continued progress but offered no new results or specific timeline. Lexicon clinical and financial update
• Negative Sentiment: Despite beating estimates, Lexicon still reported a quarterly loss, reflecting continued profitability risk as investors await clinical and regulatory progress.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently commented on LXRX shares. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Lexicon Pharmaceuticals in a report on Wednesday, October 21st. Wall Street Zen downgraded shares of Lexicon Pharmaceuticals from a "sell" rating to a "strong sell" rating in a research report on Saturday, October 31st. Zacks Research cut shares of Lexicon Pharmaceuticals from a "strong-buy" rating to a "hold" rating in a research note on Monday, August 3rd. Finally, Cantor Fitzgerald started coverage on shares of Lexicon Pharmaceuticals in a research report on Monday, September 28th. They set an "overweight" rating and a $8.00 price objective on the stock. Three investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, Lexicon Pharmaceuticals has an average rating of "Hold" and a consensus price target of $5.70.

Lexicon Pharmaceuticals Company Profile

Lexicon Pharmaceuticals, Inc is a biopharmaceutical company focused on discovering, developing and commercializing medicines for serious and chronic diseases. The company uses its drug discovery platform to identify small-molecule treatments designed to target specific biological pathways, with an emphasis on metabolic, cardiovascular and neurological conditions.

Lexicon's commercial products include INPEFA (sotagliflozin), an oral medicine approved in the United States to reduce the risk of cardiovascular death, hospitalization for heart failure and urgent heart-failure visits in certain adults with heart failure or type 2 diabetes and chronic kidney disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.